Some analysis for round 4 of #RheumJC
Overall (full 24hrs including both sessions) there were 29 total participants
- 21 people had participated in one of the three previous journal clubs
- For 6, this was their second journal club
- For 7, this was their third journal club
- For 8, this was their fourth journal club
- 8 people were brand new
- 10 different countries were represented
For the full 24 hours, there were 393 total tweets – 354 unique tweets and 39 RTs
Session 1 (4pm EST)
- 13 participants (3 Europe, 9 Americas, 1 Australia)
- 2 people participated again in session 2 (10pm EST)
- There were 129 total tweets –123 unique tweets and 6 RTs
Session 2 (10pm EST)
- 15 participants (14 Americas, 1 Australia)
- There were 224 total tweets – 195 unique tweets and 29 RTs
Symplur metrics from session 1
Symplur metrics from session 2
The next session of #RheumJC will be on Thursday, May 7th, and we’re pleased to announce we’ll be discussing an article covering a hot topic these days in rheumatology… the ability to lower or discontinue biologics in patients with rheumatoid arthritis. The article is published in the April 9th, 2015 edition of The British Medical Journal and is titled “Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial” by Noortje van Herwaarden, et al.
The article is open access and can be found at: http://www.bmj.com/content/350/bmj.h1389–0
The session will again be run with two one-hour “live chats”, however with the difference between EST and GMT shortening to 4 hours due to daylight savings in the US, the first “live chat” will be at 8pm GMT (4pm EST) and the second at 2am GMT (10pm EST).
If you are new to using Twitter, take a look at our Intro to Twitter page.
If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:
- Please remember to try to stay on topic whenever possible.
- Be polite and courteous.
- Do not violate HIPAA.
As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at firstname.lastname@example.org.